Conditional approval lets the SFDA grant a marketing authorisation on the basis of less complete clinical data than normal, subject to specific obligations, where a medicine addresses unmet need in a serious or life-threatening condition. The guidance is Version 1.0 (document 231018/V01-107-G-DS), issued 19 October 2023 and implemented 19 December 2023. Its legal basis is Chapter 3, Article 18 of the Registration Rules of Pharmaceutical, Herbal, and Health Product Manufacturers and their Products. It is one of the accelerated routes within the SFDA Regulatory Framework for Drug Approval.
The constraint to establish first: government sector only
Before assessing eligibility, note the commercial boundary. The guidance states that conditionally approved medicinal products are exclusively for government health sector supply.
That single sentence determines whether conditional approval fits a commercial plan at all. A company expecting private-sector distribution on the strength of a conditional approval has misread the pathway. It is a mechanism for public-health access, not for market entry.
Who is eligible
The guidance applies to new medicinal products, including biologics, for human use, in one of two categories:
- Products for the treatment, prevention or medical diagnosis of seriously debilitating or life-threatening diseases. Severity must be justified on objective, quantifiable medical or epidemiological grounds — a life-threatening disease can be described through mortality and life-expectancy figures, while 'seriously debilitating' requires evidence of a well-established major impact on day-to-day functioning, early or late in the disease course.
- Products to be used in emergency situations, such as a pandemic, in response to public health threats recognised by the World Health Organization or by the Saudi Ministry of Health.
The four requirements — all must be met
Conditional approval may be granted where comprehensive clinical data have not been supplied but every one of the following holds:
- The risk-benefit balance is positive. Comprehensive non-clinical and pharmaceutical data must be available — it is the clinical data that may be less complete. The SFDA may at its discretion accept incomplete preclinical or pharmaceutical data, assessed case by case.
- It is likely the applicant can provide the comprehensive clinical data, by completing ongoing studies or conducting new ones within an agreed timeframe.
- Unmet medical needs will be fulfilled — no satisfactory method of diagnosis, prevention or treatment exists, or the product offers a major therapeutic advantage over one that does.
- The public-health benefit of immediate availability outweighs the risk inherent in data still being required, with a justification assessing that impact.
Two years, extendable to a maximum of six
A conditional approval is effective for two years and is not intended to remain conditional indefinitely. Up to two extensions of two years each are available, giving a maximum conditional period of six years.
An extension must be applied for at least six months before the approval is due to end, accompanied by a report on fulfilment of the specific obligations. The extension is assessed on the benefit-risk balance and on whether the obligations are being met.
At review, one of three things happens: the product transitions to full registration once obligations are fulfilled and complete data confirm benefits continue to outweigh risks; it is withdrawn if new data show they no longer do; or an extension is granted. The SFDA can also suspend or revoke the approval where post-approval obligations are not fulfilled.
Post-approval reporting is heavier than a standard registration
Periodic safety update reporting is adapted to the validity of the conditional approval, and for the first six months after approval the company submits a monthly summary report. At minimum each report covers interval and cumulative exposure in Saudi Arabia and worldwide, interval and cumulative serious and non-serious case reports overall and by age group and special population such as pregnant women, regulatory actions taken for safety reasons, changes to reference safety information, and new, ongoing and closed signals.
This is a real operating commitment. Companies should plan the pharmacovigilance resource before applying, not after approval, because the obligations begin immediately and non-fulfilment is grounds for suspension.
Conditional approval, priority review or breakthrough?
The three are frequently conflated. Priority review expedites assessment without changing the evidence required. The Breakthrough Medicine Program provides early dialogue and a designation for products not yet registered by a stringent authority. Conditional approval is the only one of the three that grants an authorisation on incomplete clinical data — and the only one restricted to government sector supply.
Choosing between them is a strategic decision made before submission, and the answer follows from the data package and the intended market, not from which route sounds fastest.
How MRG supports a conditional approval application
MRG holds SFDA Consultation Office license CO-2023-FO-0022 and manages conditional approval end to end: testing eligibility against both categories and all four requirements, preparing the severity and unmet-need justifications on objective grounds, defining the specific obligations and the timeframe for completing the clinical data, and building the monthly and periodic safety reporting from the outset. The guidance encourages SFDA advice before submission, and we recommend using it.
For the underlying filing mechanics see SFDA drug registration in Saudi Arabia, or explore our pharmaceutical regulatory services in Saudi Arabia.
Key Takeaway
SFDA conditional approval grants a marketing authorisation on less complete clinical data for medicines addressing unmet need in seriously debilitating or life-threatening disease, or for emergency use. It requires a positive benefit-risk balance, a credible plan to complete the data, genuine unmet need, and a public-health case for immediate availability. It runs two years, extends to a maximum of six, carries monthly safety reporting for the first six months — and supply is restricted to the government health sector.
Frequently Asked Questions
Who can supply a conditionally approved medicine in Saudi Arabia?
Conditionally approved medicinal products are exclusively for government health sector supply. Conditional approval is a public-health access mechanism rather than a route to private-sector market entry, which is the point most commonly misunderstood about the pathway.
How long does SFDA conditional approval last?
Two years initially. Up to two extensions of two years each are available, giving a maximum conditional period of six years. An extension must be applied for at least six months before expiry, with a report on fulfilment of the specific obligations.
What are the requirements for SFDA conditional approval?
Four, all mandatory: a positive risk-benefit balance with comprehensive non-clinical and pharmaceutical data available; a likelihood the applicant can supply comprehensive clinical data within an agreed timeframe; genuine unmet medical need; and a public-health benefit of immediate availability that outweighs the risk of the missing data.
How is conditional approval different from priority review?
Priority review expedites the assessment but does not change the evidence required for approval. Conditional approval grants an authorisation on incomplete clinical data, subject to specific obligations, and restricts supply to the government health sector.
